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Abstract
A focal point in the safety evaluation of cosmetic ingredients includes oral repeated dose toxicity testing, which is intended 
to address the most complex human endpoints. Seven years after the full implementation of the animal testing ban for cos-
metic ingredients in the EU, there are still no alternative methods available capable of fully replacing oral repeated dose 
toxicity testing. Until this issue is resolved, the development of new cosmetic ingredients remains seriously hampered. The 
present paper describes a thorough screening of the oral repeated dose toxicity data included in safety evaluation reports of 
cosmetic ingredients addressed in the Annexes of the Cosmetics Regulation (EC) No 1223/2009, issued by the Scientific 
Committee on Consumer Safety between 2009 and 2019. The liver and the haematological system were identified as the 
potentially most frequently affected organs upon oral administration of cosmetic ingredients to animals. Evaluation of altered 
biochemical, morphological, and histopathological parameters related to hepatotoxicity indicated that the most recurrent 
events are liver weight changes, elevated liver enzymes, and alterations in serum cholesterol and bilirubin levels. Combined 
listing of affected parameters associated with steatosis and cholestasis indicated the possible occurrence of cholestasis, pro-
voked by a limited number of cosmetic ingredients. The most frequently affected parameters related to the haematological 
system were indicative of anaemia. An in-depth analysis allowed characterisation of both regenerative and non-regenerative 
anaemia, pointing to direct and indirect haematotoxicity, respectively. The results presented in this study call for prioritisa-
tion of research targeted towards the development of new approach methodologies fit for animal-free repeated dose toxicity 
evaluation of cosmetic ingredients.
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SCCS  Scientific Committee on Consumer Safety
SED  Systemic exposure dose
SEURAT  Safety Evaluation Ultimately Replacing 
Animal Testing
TTC  Threshold of toxicological concern
Introduction
The procedure for safety evaluation of cosmetic products and 
their ingredients has undergone major changes in Europe 
during the past decade. Since 11 September 2004, the 7th 
Amendment to Directive 76/768/EEC prohibits animal 
experiments of finished cosmetic products, while such test-
ing ban on cosmetic ingredients, or combinations thereof, 
entered into force from 11 March 2009 onwards (EU 1976, 
2003). At the same time, a marketing ban (i.e., the marketing 
in the EU of cosmetic products and their ingredients tested 
on animals to evaluate their safety) was introduced for all 
human health effects. The most complex endpoints, namely 
repeated dose toxicity (RDT), reproductive toxicity, and 
toxicokinetics, were exempt until 11 March 2013. The ban 
was taken up in Cosmetics Regulation (EC) No 1223/2009 
(EU 2009), despite the fact that non-animal methods capable 
of assessing those particular toxicological endpoints were 
lacking.
Today, validated non-animal methods are available for 
testing short-term and local toxicological endpoints, includ-
ing skin irritation/corrosion (1OECD 439, 431, 435, 430) 
and eye damage/irritation (OECD 491, 492, 437, 438). 
Additionally, there are validated in vitro/in chemico testing 
methods for skin sensitisation, some of which have obtained 
regulatory acceptance as integrated testing approaches 
(OECD 442D, 442C, 442E, 256). However, 7 years after the 
full implementation of the animal testing ban for cosmetic 
ingredients, non-animal methods for testing RDT [i.e., sub-
acute (28 days), sub-chronic (90 days), and chronic (85% of 
expected lifetime) studies], are still lacking.
According to Cosmetics Regulation (EC) No 1223/2009 
(EU 2009), the margin of safety (MoS) should be calculated 
to assess whether a defined exposure to a certain cosmetic 
ingredient can be considered safe. Despite the fact that the 
oral route is not the intended, nor expected, route of expo-
sure for the majority of cosmetic products, it is used as a 
worst-case scenario in the safety assessment unless robust 
dermal toxicity data are available (SCCS 2018). The MoS is 
calculated as the ratio of the point of  departuresys  (PODsys) 
over systemic exposure dose (SED).  PODsys denotes the 
point of departure for systemic toxicity of the substance 
under consideration. Typically, the no observed adverse 
effect level (NOAEL) in the most sensitive organ, histori-
cally derived through in vivo RDT testing, is used as POD 
and consequently is a key point in the overall safety assess-
ment of the cosmetic ingredient. The SED is a function of 
the concentration present in the cosmetic product, usually 
topically applied, and its dermal absorption. When the MoS 
is equal to, or greater than, 100, the substance is generally 
considered safe under the intended use conditions (SCCS 
2018).
Several EU and industry-funded projects, both completed 
and ongoing, such as the Safety Evaluation Ultimately 
Replacing Animal Testing (SEURAT),2 the Integrated 
European ‘Flagship’ Programme Driving Mechanism-based 
Toxicity Testing and Risk Assessment for the twenty-first 
century (EU ToxRisk)3 and Cosmetics Europe’s “Long 
Range Science Strategy” programme, are devoted to find-
ing non-animal approaches capable of addressing questions 
that historically have been answered through RDT testing 
(Gocht et al. 2015; Daneshian et al. 2016; Desprez et al. 
2018; Vinken 2020). It has been proposed that the break-
down of questions addressed by in vivo RDT testing into 
smaller components would greatly facilitate the develop-
ment of suitable non-animal methods for their replace-
ment (Laroche et al. 2019). In this context, identification 
of target organs of RDT (i.e., the organ where the critical 
effect occurs) as well as the potential toxicological pathways 
involved are crucial factors. A pragmatic approach to collect 
such information is by screening safety evaluation reports, 
or so-called opinions, issued by the Scientific Committee 
on Consumer Safety (SCCS). Such safety evaluations are 
performed for Annex substances of Cosmetics Regulation 
(EC) No 1223/2009, which are cosmetic ingredients where 
some concern exists with respect to human health (e.g., col-
ourants, preservatives, UV filters, and hair dyes) (EU 2008, 
2009). In each opinion, the SCCS addresses direct questions 
regarding the safety of the specific cosmetic ingredient and 
performs a safety evaluation of the ingredient with reference 
to the intended use (SCCS 2018). In the current study, data 
from the safety evaluations published by the SCCS between 
2009 and 2019 were collected with the specific aim to iden-
tify potential target organs of RDT and manifestations of the 
toxicity in those organs.
1 OECD guidelines are available via https ://www.oecd.org/env/ehs/
testi ng/oecdg uidel inesf orthe testi ngofc hemic als.htm.
2 More information regarding the project is available via https ://
www.seura t-1.eu/.
3 More information regarding the project is available via https ://
www.eu-toxri sk.eu/.
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Materials and methods
The study material consisted of 114 SCCS opinions issued 
between 22 January 2009 and 31 December 2019 dealing 
with 101 unique cosmetic ingredients in total. All informa-
tion used in this study was downloaded from the SCCS web-
site.4 Hence, no confidential data were used.
For identification of target organ(s), data were manually 
collected from oral RDT studies described in the SCCS 
opinions, thus without access to the raw data submitted to 
the SCCS. The information was sorted into a  Microsoft® 
Office Excel spreadsheet based on the organ in which the 
critical effect(s) occurred and from which a NOAEL could 
be derived. In cases of multiple target organs, the sorting 
was based on what appeared to be the most relevant and 
sensitive effect. Further analysis of the data included the list-
ing of all changes in morphological, histopathological, and 
blood biochemical parameters relevant for the top 2 affected 
organs and/or organ systems described in 88 opinions con-
taining RDT data.
Results and discussion
Identification of repeated dose toxicity studies 
described in the safety evaluation reports
Among the 101 substances covered in the SCCS opinions 
included in the study, no adequate oral RDT data for deter-
mination of an NOAEL were available for 13 cosmetic 
ingredients. For 1 of the remaining 89 substances, a read-
across approach from other routes of exposure was applied. 
Hence, 88 opinions contained oral RDT data for which an 
NOAEL determination and subsequent MoS calculation was 
feasible (Table 1).
A total of 37 28-day oral toxicity studies were available 
for 26 cosmetic ingredients, indicating that a particular 
chemical compound may have been subjected to a similar 
test more than once. For 19 of these 26 ingredients, also 
90-day oral toxicity studies were available. However, in 
many of these cases, the 28-day study was used as a dose 
range-finding study for the subsequent 90-day study. In total, 
there were 110 90-day studies available for 79 cosmetic 
ingredients. Some of the evaluated cosmetic ingredients have 
a long history of use and/or have been used in areas other 
than the cosmetics field, which might contribute to cases 
where multiple studies have been conducted for the same 
ingredient. In opinions lacking 90-day oral RDT studies, 
supporting information was provided from open literature 
(2) and through read-across from 28-day studies (5) or from 
chronic studies (2). A total of 120 teratogenicity studies were 
provided for 79 cosmetic ingredients, again suggesting that 
a specific ingredient may have been repeatedly subjected 
to similar tests. Because teratogenicity studies are specifi-
cally designed to assess the effects on maternal health, foetal 
abnormalities and/or altered growth of the foetus, they were 
not further considered in the present study. Chronic, carci-
nogenicity, and two-generation reproductive toxicity studies 
were represented to a lesser extent in the SCCS opinions, 
albeit displaying a similar pattern of studies repeated for a 
certain ingredient.
Description of target organs in oral repeated dose 
toxicity studies included in the safety evaluation 
reports
As the 90-day oral RDT studies are specifically designed 
to provide information on toxic effects and indicate target 
organs upon repeated exposure (OECD 2018), information 
on target organs and critical effects have primarily been 
retrieved from those studies. Exceptions include the nine 
opinions previously mentioned where the data described in 
the opinions were provided from open literature and through 
read-across from other oral studies. Of the 88 opinions con-
taining oral RDT data (listed in Online Resource 1), eight 
cosmetic ingredients were devoid of adverse effects at the 
maximum allowed test dose (1000  mg/kg bodyweight) 
resulting in the determination of an NOAEL and a no 
observed effect level (NOEL) at this dose for 6 and 2 ingre-
dients, respectively, while an NOAEL was set at the highest 
tested dose (< 1000 mg/kg bodyweight) for five cosmetic 
ingredients. Consequently, based on the lack of observed 
adverse effects, it was not possible to identify the target 
organ for these 13 compounds.
Critical effects and/or target organs used to set an NOAEL 
were identified through RDT studies in 75 opinions. Among 
these 75 opinions, the liver was identified as the target organ 
for 20 cosmetic ingredients, based on alterations in blood 
Table 1  Identification of repeated dose toxicity studies described in 
88 safety evaluation reports published between 2009 and 2019




28-day toxicity study 37 26
90-day toxicity study 110 79




Chronic toxicity study 15 9
Carcinogenicity study 30 16
4 SCCS opinions are available for download via https ://ec.europ a.eu/
healt h/scien tific _commi ttees /consu mer_safet y_en.
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biochemistry, including enzyme activities, and on histo-
pathological changes (e.g., vacuolisation and necrosis), mak-
ing it one of the most frequent targets of toxicity. Due to its 
anatomical proximity to the digestive tract and high blood 
flow rate, together with its key role in the biotransformation 
of xenobiotics, it is not surprising that the liver appears as a 
main target of toxicity upon repeated oral exposure (Hayes 
and Kruger 2014).
Based on aberrant haematological parameters such as 
number of blood cells, amount of haemoglobin, and mor-
phological and/or histopathological changes in the spleen, 
the haematological system and/or the spleen, often in com-
bination and, therefore, paired as one organ system, were 
found to be commonly affected. The haematological sys-
tem is complex, multicellular and in a dynamic state of cell 
proliferation, differentiation, activation, and maturation. 
The spleen is responsible for red blood cell production and 
removal of damaged blood cells (Hayes and Kruger 2014; 
Mebius and Kraal 2005). Hence, it is conceivable to assume 
that the turnover and alteration of cells in the blood, as well 
as the high blood flow through the spleen, makes the system 
vulnerable to chemical-induced systemic toxicity.
The third most affected organs, although with markedly 
lower occurrence compared to the liver and the haemato-
logical system, were demonstrated to be the kidneys. In most 
cases, this was based on histopathological changes (Fig. 1) 
such as cellular degeneration (3) and the presence of hyaline 
droplets (3) in the renal tubules. However, for the majority of 
cases, the study descriptions in the SCCS opinions did not 
allow to determine which part of the tubules were affected. 
Additionally, hyaline droplets are often seen as a non-specific 
response and thus of limited relevance to humans, especially 
when exclusively observed in male rats, which was the case for 
two out of  the three compounds. The kidneys are responsible 
for maintaining a consistent internal environment by regulating 
the body’s salt, water, and acid–base balance. This is achieved 
through blood filtration, approximately 25% of the cardiac 
output, and excretion of waste products (Barnett and Cum-
mings 2019). Moreover, the epithelial cells lining the proximal 
tubules contain a plethora of transport proteins, often lead-
ing to accumulation of chemical compounds, resulting in a 
high concentration of chemicals within the tubular epithelial 
cells relative to that in plasma (Barnett and Cummings 2019; 
Hayes and Kruger 2014) which may partly explain the cellular 
degeneration observed in the renal tubules. Collectively, these 
properties make the kidneys sensitive to toxicants and, thus, 
not an unexpected target for systemic toxicity.
Identification of morphological, histopathological, 
and biochemical changes related to hepatotoxicity 
in oral repeated dose toxicity studies described 
in the safety evaluation reports
Following the identification of the liver as the main target 
for toxicity in oral RDT studies, the relevance of this finding 
was further investigated by listing potentially toxicological 
parameters related to hepatotoxicity as described in the SCCS 
opinions (Fig. 2a and b). In addition to the 20 cosmetic ingre-
dients demonstrated to elicit a critical effect in the liver, 29 
additional ingredients of the 88 opinions containing oral RDT 
data also altered one or more parameters related to hepatotox-
icity, resulting in 49 liver-affecting compounds in total. For 
29 of the 88 cosmetic ingredients, a combination of changes 
in parameters related to hepatotoxicity and haematotoxicity 
















Number of cosmec ingredients
Fig. 1  Identification of target organs and critical effects of 75 cosmetic ingredients from oral repeated dose toxicity studies described in the 
safety evaluation reports issued between 2009 and 2019
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was seen. Alterations in serum cholesterol and bilirubin levels 
were the most commonly observed biochemical modifications 
(Fig. 2a), while altered liver weight represented the most fre-
quently occurring morphological change (Fig. 2b). Deviating 
levels of one or more liver enzymes were also commonly seen 
(Fig. 2a), i.e., for 28 substances in total. However, it should be 
noted that these safety evaluations have not been designed for 
this specific purpose and the relevance of observed alterations 
in individual parameters for characterising liver injury must be 
seen as limited. For example, hepatocellular hypertrophy can 
reflect adaptive responses to a compound due to, e.g., enzyme 
induction (Hall et al. 2012). Changes in liver weight can be 
attributed either to transient adaptive effects or an unfavourable 
taste of the compound causing a reduced food intake with sub-
sequent reduction in body weight of the test animals, thereby 
also affecting organ weight (Cattley and Cullen 2013; Vinken 
et al. 2012). Unaccompanied, many of these deviations are 
not necessarily regarded as toxicologically relevant and do not 
always imply adversity. Yet, elevated enzyme activities such 
as alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) reflect hepatocyte damage and may provide a 
first indication of liver toxicity (David and Hamilton 2010). 
Consequently, changes in individual parameters have rather 
limited significance for characterising potential (liver) injury. 
To accurately identify adversities, a battery of tests that detect 
clinically important biochemical, histopathological, and mor-
phological parameters needs to be considered.
Certain combinations of effects might, however, be indic-
ative of specific adverse effects. Concomitant increases in 
serum AST, cholesterol, and triglycerides, alongside fat 
accumulation in hepatocytes, resulting from impaired bal-
ance between the rate of synthesis and the release of triglyc-
erides from the hepatocytes, could imply steatosis-inducing 
potential of a compound (Hayes and Kruger 2014; Ipsen 
et al. 2018). Likewise, simultaneous increases in serum 
alkaline phosphatase (ALP), gamma-glutamyl transferase 
(GGT), and bilirubin, in addition to hepatocellular necro-
sis, are predominant features of cholestatic liver injury, i.e., 
hepatocellular accumulation of bile (Boone et al. 2005; 
Greim 2008; Hayes and Kruger 2014; Robles-Diaz et al. 
2015). In this context, several compounds covering a wide 
chemical space and various application areas have been 
found to induce liver steatotic and cholestatic effects (Al-
Eryani et al 2015; Vilas-Boas et al. 2019). Cosmetic ingre-
dients provoking a change in one or more parameters poten-
tially associated with steatosis and cholestasis are depicted 
in Tables 2 and 3, respectively. Based on these combined 
observations, none of the 49 cosmetic ingredients triggered 
changes in the combination of parameters related to steatosis 
to a degree prospectively raising concern, i.e., affecting three 
out of four parameters (Vinken et al. 2012). Two out of the 
49 liver-affecting cosmetic ingredients were found to alter 
three or more of the parameters associated with cholestasis, 
namely 2,7-naphthalenediol and Basic red 51, and could, 
therefore, be considered as plausible cholestasis-inducing 
compounds (SCCS 2010a, 2011). 
Identification of morphological, histopathological, 
and biochemical changes related 
to the haematological system and the spleen 
in oral repeated dose toxicity studies described 
in the safety evaluations
As holds for the liver, the parameters possibly related to 
haematotoxicity described in the SCCS opinions were 
listed. In total, 42 of the 88 cosmetic ingredients induced 
changes in one or more parameters associated with the 
haematological system following oral RDT testing. The 
most frequently observed morphological and histopatho-
logical changes in the spleen were alterations in weight 
and occurrence of haematopoiesis (Fig. 3b). While both 
effects can be caused by a large variety of insults, the 









Number of cosmec ingredients






Number of cosmec ingredientsBA
Fig. 2  a Identification of changes in clinical parameters possi-
bly linked to hepatotoxicity in oral repeated dose toxicity studies 
described for the 49 liver-affecting cosmetic ingredients in safety 
evaluation reports issued between 2009 and 2019. b Identification of 
morphological and histopathological changes possibly linked to hepa-
totoxicity in oral repeated dose toxicity studies described for the 49 
liver-affecting cosmetic ingredients in safety evaluation reports issued 
between 2009 and 2019
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Table 2  Identification of cosmetic ingredients provoking a change in at least one parameter associated with steatosis based upon alterations 
observed in oral repeated dose toxicity studies described for the 49 liver-affecting cosmetic ingredients in safety evaluation reports issued 
between 2009 and 2019




Hair dyeing ingredient used as a precursor for hair 
dyeing products. The reaction can be acceler-
ated by the addition of an oxidising agent (e.g., 





Used as a fragrance in perfumes and cosmetics x
Basic brown 17 Hair dyeing ingredient used as a direct dye for hair 
colouring products
x x
Basic red 51 Hair dyeing ingredient used in direct hair dye for-
mulations and in oxidative hair dyes after mixing 
with the oxidative agent
x x
Basic violet 2 Hair dyeing ingredient used as a non-reactive hair 
colouring agent in non-oxidative hair dye-formu-
lation and oxidative hair dye formulations. Also 
used as a colourant (CI 42,520) in cosmetic prod-






Used as a UV filter (λmax = 310 nm) proposed to 





Used as a fragrance ingredient in many compounds 
for cosmetic products as well as in non-cosmetic 





Used as a disinfectant in mouthwashes cosmetic 
products up to a concentration of 0.1%, all other 
oral hygiene cosmetic products up to a con-
centration of 0.5%, skin lotions and creams up 
to a concentration of 0.2% and anti-perspirant 




Used as volatile excipient in cosmetic products. 
It can have many different functions in cos-
metic products including antistatic, emollient, 
humectant, solvent, viscosity controlling, and 
hair conditioning
x
EcoG + Used as a preservative in the internal parts of pack-
aging containers (i.e., the parts of the packaging 
in direct contact with the cosmetic product)
x
HC blue 15 Hair dyeing ingredient used in oxidative hair dyes 
as a non-reacting component
x x
HC yellow 13 Hair dyeing ingredient used as a hair colouring 
agent ("direct dye") in non-oxidative and oxida-




Hair dyeing ingredient used as a direct dye in hair 
dye formulations and as a non-reactive dye in 





Hair dyeing ingredient used in oxidative hair dye 
formulations after mixing with the developer 
containing hydrogen peroxide
x
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Table 2  (continued)









nylenediamine and its 
dihydrochloride salt 
(A165)













Hair dyeing ingredient used as a direct hair dye for 
hair colouring products. Used in oxidative hair 
dye formulations with and without mixing with 




Used as a solvent and a surfactant in cosmetic 
products
x
o-Aminophenol Hair dyeing ingredient used in oxidative hair dye 
formulations
x
Phenoxyethanol Used as a preservative in cosmetic formulations at 




Hair dyeing ingredient used in oxidative hair dye 
formulations (precursor)
x
Vetiveryl acetate Used as a fragrance in perfumes and cosmetics x
*Aspartate aminotransferase
**Triglycerides
former is considered as a sensitive indicator of immune 
toxicity (Kim 2010; Michael et al. 2007). The most com-
monly affected haematological parameters were changes 
in red blood cell count (RBC), mean concentration of 
haemoglobin (MCH) in red blood cells, and haematocrit 
(i.e., the ratio of the volume of red blood cells to the total 
blood volume) (Fig. 3a). When decreased, all these param-
eters are indicative of anaemia, albeit a correct diagnosis 
requires a more complex assessment (Broadway-Duren and 
Klaassen 2013; Cascio and DeLoughery 2017) with addi-
tional tests generally not included in RDT studies. Com-
monly analysed parameters related to the haematological 
system can be used to classify the suspected anaemia as 
regenerative or non-regenerative (Grimes and Fry 2015). 
The former encompasses reduced levels of circulating red 
blood cells and/or other red blood cell parameters such 
as haemoglobin and haematocrit, which is accompanied 
by an increase in immature blood cells, i.e., reticulocytes. 
If the regenerative response is potent enough to counter-
act the decreased levels of red blood cells, a regenerative 
anaemia can be diagnosed based on increased erythrocyte 
mean cell volume (MCV) and subnormal mean corpuscu-
lar haemoglobin concentration (MCHC). On the contrary, 
in non-regenerative anaemia, no increase in the levels of 
reticulocytes is seen. Non-regenerative anaemia occurs less 
often as a result of primary haematotoxicity, but is more 
frequently a complication of various non-haematologic 
diseases, e.g., inflammation (Grimes and Fry 2015). In 
Table 4, the cosmetic ingredients that provoked changes in 
the above-mentioned haematological parameters are listed. 
Alterations indicative of non-regenerative anaemia (i.e., 
anaemia with no concomitant increase in reticulocytes) 
were observed for 2,7-naphthalenediol, erythrosine (CI 
45430), disperse violet 1 (1,4-diamino-anthraquinone), HC 
red 7, and sodium perborate and perboric acid. This is in 
line with the finding that 2,7-naphthalenediol, erythrosine 
(CI 45430), and disperse violet 1 (1,4-diamino-anthraqui-
none) are believed to target organs other than the haema-
tological system (Online Resource 1). Conversely, HC red 
7, and sodium perborate and perboric acid are believed to 
target the haematological system and may induce anaemia 
only as a secondary effect. Again, it is important to keep 
in mind that these safety evaluation reports of cosmetic 
ingredients have not been designed to diagnose specific 
diseases, but rather to describe general toxicity, and thus, 
the results need to be considered with caution. 
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Table 3  Identification of cosmetic ingredients provoking a change in 
at least one parameter associated with cholestasis based on alterations 
observed in oral repeated dose toxicity studies described for the 49 
liver-affecting cosmetic ingredients in safety evaluation reports issued 
between 2009 and 2019
*Alkaline phosphatase
**Gamma-glutamyl transferase
Cosmetic ingredient Function ↑ALP* ↑GGT* ↑Bilirubin Hepato-
cellular 
necrosis
1,5-Naphthalenediol Hair dyeing ingredient used in oxidative and non-
oxidative hair dye formulations
x
2,6-Dihydroxyethylaminotoluene Hair dyeing ingredient used as a precursor for hair 
colours. It reacts with primary intermediates to 
form the final dye-stuff. The reaction can be accel-
erated by the addition of an oxidising agent (e.g., 
hydrogen peroxide), but it can also be achieved by 
air oxidation
x
2,7-Naphthalenediol Used in oxidative and non-oxidative hair dye formu-
lations with a maximum on-head concentration of 
1%
x x x
5-Amino-6-chloro-o-cresol Used as a precursor for hair dyeing products. The 
reaction can be accelerated by the addition of an 
oxidising agent (e.g., hydrogen peroxide), but can 
also be achieved by air oxidation
x
Basic brown 17 Hair dyeing ingredient used as a direct dye for hair 
colouring products
x x
Basic red 51 Hair dyeing ingredient used in direct hair dye formu-
lations and oxidative hair dyes after mixing with 
the oxidative agent
x x x
Citric acid (and) silver citrate Used as a preservative system in aqueous leave-on 
and rinse-off cosmetic products. Citric acid and 
silver citrate is used in deodorants
x
Diethylene glycol monoethyl ether Used in cosmetics and dermatological preparations 
and as a solvent in some medicine products. Its 
physical properties make DEGEE useful to solubi-
lise lipophilic and hydrophilic compounds. Moreo-
ver, DEGEE enhances the percutaneous absorption 
through the skin and mucosal barriers
x
EcoG + Used as a preservative in the internal parts of pack-
aging containers (i.e., the parts of the packaging in 
direct contact with the cosmetic product)
x
Hydroxyethyl-2-nitro-p-toluidine Used as a direct dye in hair dye formulations at a 
maximum concentration of 1% and as a non-
reactive dye in oxidative hair dye formulations at a 
maximum concentration of 1%, after dilution with 
the oxidative agent
x x
Hydroxyethyl-3,4-methylenedioxyaniline HCl Hair dyeing ingredient used in oxidative hair dye 
formulations after mixing with the developer con-
taining hydrogen peroxide
x
Hydroxypropyl p-phenylenediamine and its 
dihydrochloride salt (A165)





Used as a UV filter in personal care products, includ-
ing sun care cosmetic formulations at a maximum 
concentration of 3% w/w
x
N-Methyl-2-pyrrolidone Used as a solvent and a surfactant in cosmetic 
products
x
Phenoxyethanol Used as a preservative in cosmetic formulations at a 
maximum concentration of 1.0%
x
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Conclusion
The goal of the current study was to identify the main target 
organs and/or critical effects as well as to characterise the 
manifestations of toxicity of cosmetic ingredients in these 
organs in oral RDT studies. RDT data were collected from 
safety evaluation reports published by the SCCS between 
2009 and 2019. Not surprisingly, it was found that the most 
frequently affected organs by cosmetic ingredients were 
the liver and the haematological system, whose inherent 
physiological functions make them susceptible to toxicants 
(Cattley and Cullen 2013; Hayes and Kruger 2014; Mebius 
and Kraal 2005). It is well known that drug-induced liver 
injury remains a common cause of the withdrawal of drugs 
in pre-clinical and even clinical phases of drug development 
(Lee 2013; Onakpoya et al., 2019). It has also been reported 
that chemicals from various other application areas could 
trigger liver adversities such as steatosis and cholestasis 
(Al-Eryani et al. 2015; Vilas-Boas et al. 2019). Here, for 
cosmetic ingredients, certain combinations of changes in 
relevant parameters that could indicate liver steatosis and 
cholestasis were collected (Tables 2 and 3) for all potentially 
liver-affecting compounds (49). The liver’s complexity and 
diverse functions, in combination with its varied response 
to injury, require careful consideration of multiple param-
eters to ensure scientifically valid results. It should be further 
stressed that the parameters available in the SCCS opinions 
constitute only a limited part of the clinically relevant infor-
mation addressed to diagnose liver steatosis and cholestasis. 
This also holds true for possible adverse effects associated 
with the haematological system. The identification of the 
kidneys as the third most commonly affected organs was 
based on various histopathological changes for which no 
clear pattern could be identified. Therefore, characterisation 
of the toxic effects is limited to the observation that the most 
prominent alterations were the presence of hyaline droplets 
and cellular degeneration in the renal tubules. As previously 
mentioned, the studies used in the safety evaluation reports 
are not designed to investigate specific adverse effects, 
but rather indicate a general capability of a compound to 
induce harmful effects. Therefore, it is of utmost impor-
tance to interpret the findings presented here with caution 
to avoid incorrect conclusions. Nevertheless, two cosmetic 
ingredients, i.e., 2,7-naphthalenediol and Basic red 51, were 
demonstrated to affect three or more parameters associated 
with cholestasis, therefore possibly indicating a cholestasis-
inducing potential (SCCS 2010a, 2011). Moreover, HC red 
7, and sodium perborate and perboric acid provoked changes 
indicative of indirect haematotoxic effects. Indeed, in the 
safety evaluation of HC red 7, additional effects are men-
tioned that could be of interest for further investigations 
(SCCS 2009). However, the studies in the safety evaluation 
of sodium perborate and perboric acid are old and poorly 
described; therefore, no conclusions can be drawn in this 
regard (SCCS 2010b). Overall, the outcome of the present 
study is in line with a screening of SCCS opinions published 
between 2000 and 2009 (Vinken et al. 2012). In fact, both 
2,7-naphthalenediol and Basic red 51 were previously identi-
fied as plausible cholestasis-inducing compounds, meaning 
that they have been evaluated multiple times (Vinken et al. 
2012). In this respect, repeated evaluations of a compound 
are a common event, as 74 of the total number of compounds 
(101) included in the current screening have been addressed 
by the SCCS, or its predecessors, more than once. There are 
various reasons for the re-evaluation of a cosmetic ingre-
dient, for instance due to inadequate provision of data for 
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Fig. 3  a Identification of haematological changes possibly linked 
to toxic effects in the haematological system as described in oral 
repeated dose toxicity studies for the 42 haematology-affecting cos-
metic ingredients in safety evaluation reports issued between 2009 
and 2019. b Identification of morphological and histopathological 
changes possibly linked to toxic effects in the spleen described in 
oral repeated dose toxicity studies for the 42 haematology-affecting 
cosmetic ingredients in safety evaluation reports issued between 
2009 and 2019. *Red blood cells. **Mean corpuscular haemoglobin. 
***Mean corpuscular volume. ****Mean corpuscular haemoglobin 
concentration
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Table 4  Identification of cosmetic ingredients provoking a change 
in parameters commonly used for the diagnosis of anaemia based on 
alterations observed in oral repeated dose toxicity studies described 
for the 42 haematology-affecting cosmetic ingredients in safety evalu-
ation reports issued between 2009 and 2019
Cosmetic ingredient Function ↓Haematocrit/RBC/
mean haemoglobin*
↑MCV** ↓MCHC*** ↑Reticulocytes
1-Hexyl 4,5-diamino pyrazole sulphate Hair dyeing ingredient used as an oxi-
dative hair colouring agent (precur-
sor). The oxidative colouring agent 
and the developer are mixed at a ratio 




Hair dyeing ingredient used in oxida-
tive hair dye formulations after mix-
ing with peroxide
x
2,6-Diaminopyridine Hair dyeing ingredient used in oxida-
tive hair colouring products after 
mixing in a 1:1 ratio with hydrogen 
peroxide just prior to use
x x x
2,7-Naphthalenediol Hair dyeing ingredient used in oxida-





Hair dyeing ingredient used in oxida-
tive hair dye formulations after 
mixing the developer containing 
oxidative agent
x x
4-Chlorooresorcinol Hair dyeing ingredient used as a cou-
pler in oxidative hair dye formula-
tions
x x
4-Nitrophenyl aminoethylurea Hair dyeing ingredient used as direct 
dye in semi-permanent hair formula-
tions and as a hair colouring agent 
(direct dye) in oxidative hair dye 
formulations
x x
5-Amino-6-chloro-o-cresol Hair dyeing ingredient used as a pre-
cursor for hair dyeing products
x x x
Acid black 1 Hair dyeing ingredient used as a direct 
hair colouring agent in non-oxidative 
hair dye formulations
x x
Acid orange 7 Hair dyeing ingredient used as a direct 
hair colouring agent in non-oxidative 
as well as in oxidative hair dye 
formulations
x
Basic red 76 Hair dyeing ingredient used as a direct 
dye for hair colouring products
x x
Basic violet 2 Hair dyeing ingredient used as a non-
reactive hair colouring agent in non-
oxidative hair dye-formulation and in 
oxidative hair dye formulations. Also 
used as a colourant in cosmetic prod-
ucts intended to come into contact 
only briefly with the skin
x x
Basic yellow 57 Hair dyeing ingredient used as a direct 
dye for hair colouring products
x x
CI 45,430, erythrosine Used as a red colour additive in 
cosmetics
x
Disperse violet 1 (1,4-diamino-anth-
raquinone)
Hair dyeing ingredient used as a hair 
colour in semi-permanent hair dye 
formulations
x
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safety evaluation in the first submission or due to a request 
from the industry for an extension of the allowed use con-
centration of the specific ingredient.
Since 2013, the animal testing ban has largely impeded 
the marketing of new cosmetic ingredients. This innova-
tion issue will remain until there are suitable non-animal 
methods that address the most complex human toxicologi-
cal endpoints that historically have been evaluated with 
animal RDT testing. Due to the complex interactions in 
a whole organism, it is very unlikely to find a one-to-one 
conversion from one in vivo to one in vitro test as replace-
ment of RDT testing. Instead, it is envisaged that human-
based in silico, in vitro, and in chemico approaches, col-
lectively known as new approach methodologies (NAMs), 
will comprise the next generation risk assessment 
(NGRA). Although scientific challenges remain to be tack-
led before NAMs are used by default in safety evaluations 
and advantages with their use, such as an increased rel-
evance to human health, becomes evident. Indeed, NAMs 
have shown great promise to provide a large amount of 
data to fill information gaps in both hazard and exposure 
assessments (Rogiers et al. 2020). NGRA is anticipated 
to be hypothesis-driven and exposure-led, including mul-
tiple NAMs which are integrated and combined in novel 
approaches (Dent et al. 2018). Methods such as exposure-
based waiving using thresholds of toxicological concern 
(TTC) for structurally related compounds and chemicals 
belonging to a defined chemical space may be satisfac-
tory in case of very limited exposures (Kroes et al. 2007). 
Grouping of chemicals for read-across purposes can be 
performed at different levels of biological activity (e.g., 
common target organ, common critical effect, or mode of 
action) (Bal-Price and Meek 2017). Information about the 
effects of cosmetic ingredients on target organs will facili-
tate the development of NAMs, as they should be chal-
lenged with cosmetic ingredients as a proof-of-concept 
exercise, thereby making information on expected target 
organs and critical effect(s) essential. Hence, the results of 
this study call for prioritising the development of NAMs 
suitable to address biological activity and toxicity pro-
voked by cosmetic ingredients in the liver and the haema-
tological system.
Table 4  (continued)
Cosmetic ingredient Function ↓Haematocrit/RBC/
mean haemoglobin*
↑MCV** ↓MCHC*** ↑Reticulocytes
HC red 13 Hair dyeing ingredient used as a non-
reactive hair colouring agent (“direct 
dye”) in semi-permanent hair dye 
formulations and oxidation hair dye 
formulations
x x
HC red 7 Hair dyeing ingredient used in semi-
permanent hair dye formulations
x
HC yellow 2 Hair dyeing ingredient used in non-
oxidative hair dye-formulation and 
oxidative formulations
x x x
HC yellow 7 Hair dyeing ingredient used in semi-




Hair dyeing ingredient used in oxida-
tive hair dye formulations after 






Used as a UV filter in personal care 
products, including sun care cos-
metic formulations at a maximum 
concentration of 3% w/w
x x x
Picramic acid and sodium picramate Hair dyeing ingredient used as a direct 
hair colouring agent in non-oxidative 
as well as in oxidative hair dye 
formulations
x x x x
Sodium perborate and perboric acid Hair dyeing ingredient used in oxida-
tive hair colouring products after 
mixing with water just prior to use
x
*Red blood cell count
**Mean corpuscular volume
***Mean corpuscular haemoglobin concentration
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